| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/27/2009 | US20090214500 Prevention and treatment of osteochondrosis in animals and humans |
| 08/27/2009 | US20090214496 Bmx/etk tyrosine kinase gene therapy materials and methods |
| 08/27/2009 | US20090214495 Vascular endothelial growth factor-d (vegf)-d and functionally fragments thereof for bone repairing |
| 08/27/2009 | US20090214488 Methods and compositions for treating basement membrane disorders |
| 08/27/2009 | US20090214486 Serum Response Factor and Myocardin Control Alzheimer Cerebral Amyloid Angiopathy |
| 08/27/2009 | US20090214477 Human Marker Genes and Agents for Diagnosis, Treatment and Prophylaxis of Cardiovascular Disorders and Artherosclerosis |
| 08/27/2009 | US20090214474 Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| 08/27/2009 | US20090214466 Methods of Alleviating Disorders and Their Associated Pain |
| 08/27/2009 | US20090214465 Quinoxaline Derivatives as Antitumor Agents |
| 08/27/2009 | US20090214463 Latent phase viral interleukin-10-(VII-10) and uses thereof |
| 08/27/2009 | US20090214460 Composition Comprising a Monomer Compound Exhibiting an Optical Property, Method Making Use of Said Composition, a Monomer Compound and a Polymer Containing Said Monomer Compound and the Use Thereof |
| 08/27/2009 | US20090214452 Arginine Heteromers for Topical Administration |
| 08/27/2009 | US20090214446 Cyclodextrin inclusion complexes and methods of preparing same |
| 08/27/2009 | US20090214444 Poly aromatic sodium channel blockers |
| 08/27/2009 | US20090214443 Method for retarding systemic delivery rate for easily absorbable active agents |
| 08/27/2009 | US20090214442 Oral Transmucosal Nicotine Dosage Form |
| 08/27/2009 | US20090214439 Fluorinated Carbohydrates and Their Use in Tumor Visualization, Tissue Engineering, and Cancer Chemotherapy |
| 08/27/2009 | US20090214435 Recombinant vector expressing MDR1 shRNA and thymidine kinase and use thereof |
| 08/27/2009 | US20090214431 Identification of ergothioneine transporter and therapeutic uses thereof |
| 08/27/2009 | US20090214427 Novel peptides |
| 08/27/2009 | US20090214425 Tumor therapy with replication competent sindbis viral vectors |
| 08/27/2009 | US20090214419 Self-assembled biodegradable polymersomes |
| 08/27/2009 | DE202009007976U1 Neue Pharmazeutika und Arzneimittelzubereitungen, welche die Tumorzellproliferation und/oder Tumorvaskularisation hemmen, und ihre Wirkung als Multi-Kinase-Inhibitoren New pharmaceuticals and pharmaceutical compositions which inhibit tumor cell proliferation and / or tumor vascularization, and its effect as a multi-kinase inhibitors |
| 08/27/2009 | DE202008017304U1 Oral zerfallender Film zur therapeutischen Anwendung von Antiparasitika bei Tieren Oral disintegrating film for the therapeutic use of antiparasitic agents in animals |
| 08/27/2009 | DE202007018859U1 Präparat zur Behandlung von hyperplastischen Vorgängen in der Gebärmutterschleimhaut Preparation for the treatment of hyperplastic processes in the endometrium |
| 08/27/2009 | DE102008010221A1 New heteroaryl-substituted piperidine compounds are protease-activated receptor antagonists useful for the treatment and/or prophylaxis of e.g. cardiovascular diseases, thromboembolic diseases, tumors, stroke, hypertension and asthma |
| 08/27/2009 | DE102008000351A1 Preparing ebastine containing granules, useful to treat e.g. allergic rhinitis, comprises preparing granules from a solution of ebastine in cyclic ether solvent and a powder of one or more existing solid carrier materials, and drying |
| 08/27/2009 | CA2753021A1 Medicament |
| 08/27/2009 | CA2752868A1 Treatment of energy utilization disease |
| 08/27/2009 | CA2750762A1 Treatment of neural diseases or conditions |
| 08/27/2009 | CA2716515A1 Amine and ether compounds which modulate the cb2 receptor |
| 08/27/2009 | CA2716514A1 Hiv protease inhibitor and cytochrome p450 inhibitor combinations |
| 08/27/2009 | CA2716368A1 Genetic polymorphisms associated with stroke, methods of detection and uses thereof |
| 08/27/2009 | CA2716367A1 Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
| 08/27/2009 | CA2716349A1 Methods for inhibiting drug degradation |
| 08/27/2009 | CA2716348A1 Diamide inhibitors of cytochrome p450 |
| 08/27/2009 | CA2716347A1 Amino acid inhibitors of cytochrome p450 |
| 08/27/2009 | CA2716332A1 Compounds and compositions as modulators of gpr119 activity |
| 08/27/2009 | CA2716330A1 Compounds and compositions as modulators of gpr119 activity |
| 08/27/2009 | CA2716326A1 Ultra-small rnas as toll-like receptor-3 antagonists |
| 08/27/2009 | CA2716321A1 Methods for treating cancer using combination therapy |
| 08/27/2009 | CA2716320A1 Selective androgen receptor modulators |
| 08/27/2009 | CA2716288A1 Copper-organic complexes, use thereof as antitumor agents and for protecting healthy tissue from ionizing radiation |
| 08/27/2009 | CA2716270A1 Substituted indole derivatives |
| 08/27/2009 | CA2716230A1 Nitrogen-containing bycyclic compounds active on chronic pain conditions |
| 08/27/2009 | CA2716215A1 Compound (r) -n*6*-ethyl-6, 7-dihydro-5h-indeno (5, 6- d) thiazole-2, 6-diamine and the use as antipsychotics |
| 08/27/2009 | CA2716110A1 Ophthalmic nsaids as adjuvants |
| 08/27/2009 | CA2716080A1 Cns pharmaceutical compositions and methods of use |
| 08/27/2009 | CA2716047A1 Androgen receptor-ablative agents |
| 08/27/2009 | CA2716019A1 Antitumoral agents with a benzophenanthridine structure and formulations containing them |
| 08/27/2009 | CA2716015A1 Kinase protein binding inhibitors |
| 08/27/2009 | CA2715962A1 Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis |
| 08/27/2009 | CA2715947A1 Heterocyclic inhibitors of stearoyl-coa desaturase |
| 08/27/2009 | CA2715885A1 Novel compounds and methods for therapy |
| 08/27/2009 | CA2715872A1 Benzodiazepine compound and pharmaceutical composition |
| 08/27/2009 | CA2715771A1 Adrenomedullin production enhancer |
| 08/27/2009 | CA2715760A1 Solid preparation for oral administration |
| 08/27/2009 | CA2715747A1 B ring reduced-d ring oxidized tetrapyrollic photosensitizers for photodynamic therapy and tumor imaging |
| 08/27/2009 | CA2715675A1 Sgk1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas |
| 08/27/2009 | CA2715657A1 Novel polymorphs and processes for their preparation |
| 08/27/2009 | CA2715638A1 Cardioplegia solution for cardiac surgery |
| 08/27/2009 | CA2715634A1 Blood substitute solution |
| 08/27/2009 | CA2715557A1 Inhibitors of the chemokine receptor cxcr3 |
| 08/27/2009 | CA2715486A1 Composition for modulating stem cell growth with prostaglandins |
| 08/27/2009 | CA2715269A1 Anti-infective catheters |
| 08/27/2009 | CA2715192A1 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain |
| 08/27/2009 | CA2715181A1 Combination therapy 238 |
| 08/27/2009 | CA2715128A1 Anti-obesity compositions comprising orlistat and various natural products |
| 08/27/2009 | CA2714743A1 Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| 08/27/2009 | CA2714703A1 Compounds and compositions as modulators of gpr119 activity |
| 08/27/2009 | CA2714700A1 Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| 08/27/2009 | CA2714668A1 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres |
| 08/27/2009 | CA2714654A1 Chlorothiophene-amides as inhibitors of coagulation factors xa and thrombin |
| 08/27/2009 | CA2714608A1 Combination comprising paclitaxel for treating ovarian cancer |
| 08/27/2009 | CA2714479A1 Compounds that are erk inhibitors |
| 08/27/2009 | CA2714215A1 Novel aminopyridine derivatives having aurora a selective inhibitory action |
| 08/27/2009 | CA2714122A1 Modulators of the histamine h3 receptor useful for the treatment of disorders related thereto |
| 08/27/2009 | CA2713716A1 Modulators for amyloid beta |
| 08/27/2009 | CA2713412A1 Amide derivative and pharmaceutical composition containing the same |
| 08/27/2009 | CA2713187A1 Oxazolidinone derivatives |
| 08/27/2009 | CA2713184A1 2-aza-bicyclo[2.2.1]heptane derivatives |
| 08/27/2009 | CA2713182A1 Azatricyclic antibiotic compounds |
| 08/27/2009 | CA2712714A1 Folates, compositions and uses thereof |
| 08/27/2009 | CA2712640A1 Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| 08/27/2009 | CA2712228A1 4,5-dihydro-oxazol-2-yl amine derivatives |
| 08/27/2009 | CA2711367A1 Imidazobenzazepine cgrp receptor antagonists |
| 08/27/2009 | CA2708281A1 Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
| 08/27/2009 | CA2707853A1 Novel diazeniumdiolate derivatives, method for the preparation thereof and pharmaceutical compositions containing the same |
| 08/26/2009 | EP2093294A1 Nucleotide and protein sequences of Nogo genes and methods based thereon |
| 08/26/2009 | EP2093292A2 Inhibition of specific histone deacetylase isoforms |
| 08/26/2009 | EP2093248A1 Method for removing organic solvent |
| 08/26/2009 | EP2093228A1 Pyrroline-2-one derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof |
| 08/26/2009 | EP2093225A1 Process for preparing crystalline eletriptan hydrobromide form ß |
| 08/26/2009 | EP2093224A1 Process for preparing eletriptan hydrobromide form beta |
| 08/26/2009 | EP2093222A1 Polyisoprenoid epoxides useful for decreasing cholesterol and/or increasing coenzyme Q biosynthesis |
| 08/26/2009 | EP2093220A2 Inhibitors of fatty acid amide hydrolase |
| 08/26/2009 | EP2093218A1 Arylalkyl substituted imidazolidinones |
| 08/26/2009 | EP2093217A1 Polymorph and solvates of aripiprazole |
| 08/26/2009 | EP2093214A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 08/26/2009 | EP2093212A1 Elansolids, novel natural metabolites of flexibacter and antibiotically active derivatives thereof |